TrialClinical ophthalmology (Auckland, N.Z.)2021

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.

John Sheppard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.